Advertisement
Screener

AVALO THERAPEUTICS, INC. (AVTX) Graph

AVTX Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue (m); Cost of revenue (m); Research and development (m); Selling, general and administrative (m).
  • 2026-03-31: Revenue (m); Cost of revenue (m); Research and development (m); Selling, general and administrative (m).
  • 2025-12-31: Revenue $59.00K*; Cost of revenue (m); Research and development (m); Selling, general and administrative (m).
  • 2025-09-30: Revenue $0.00; Cost of revenue (m); Research and development (m); Selling, general and administrative (m).

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30(m)(m)(m)(m)(m)$18.00K-$36.36M
2026-03-31(m)(m)(m)(m)(m)$12.00K-$19.63M
2025-12-31$59.00K*(m)(m)(m)(m)$130.00K*-$13.72M*
2025-09-30$0.00(m)(m)(m)(m)$11.00K-$30.63M
2025-06-30(m)$0.00(m)(m)(m)$16.00K-$20.77M
2025-03-31(m)(m)(m)(m)(m)$8.00K-$13.15M
2024-09-30$249.00K-$714.00K(m)(m)(m)-$14.00K$23.04M
2024-06-30$0.00$343.00K(m)(m)(m)$7.00K$98.46M
2024-03-31$0.00-$80.00K(m)(m)(m)$7.00K-$121.29M
2023-12-31(m)(m)(m)$2.68M*(m)(m)(m)
2023-09-30$236.00K$247.00K(m)$2.49M(m)$8.00K-$5.23M
2023-06-30$643.00K$708.00K(m)$2.43M(m)$7.00K-$8.19M
2023-03-31$475.00K$551.00K(m)$2.71M(m)$8.00K-$9.96M
2022-09-30$14.95M$528.00K(m)$3.28M(m)$5.00K$3.19M
2022-06-30$1.03M$1.57M(m)$2.78M(m)$5.00K-$12.99M
2022-03-31$1.17M$720.00K(m)$11.68M(m)$9.00K-$22.05M
2021-09-30$1.35M$908.00K(m)$5.93M(m)$8.00K-$17.39M
2021-06-30$3.35M$83.00K(m)$7.40M(m)-$199.00K-$17.11M
2021-03-31$473.00K$77.00K$2.50M(m)(m)$11.00K-$30.68M
2020-09-30$1.11M$77.00K(m)(m)(m)$3.00K-$13.46M
2020-06-30$1.34M$78.00K(m)(m)(m)-$454.00K-$13.28M
2020-03-31$2.75M$66.00K(m)(m)(m)-$2.16M-$21.12M
2019-12-31(m)-$3.81M*(m)(m)(m)(m)(m)
2019-09-30$2.20M$132.38K(m)(m)$9.33M$121.64K-$4.02M
2019-06-30$1.39M-$1.50M(m)(m)$10.43M$53.45K-$6.22M
2019-03-31$2.58M$752.55K$3.40M(m)$12.43M$130.67K-$7.45M
2018-09-30$4.07M$3.11M(m)(m)$28.39M$52.41K-$24.60M
2018-06-30$4.79M$1.42M$1.08M(m)$10.54M$16.35K-$6.01M
2018-03-31$4.48M$863.62K$1.65M(m)$8.24M$23.31K-$3.88M
2017-12-31(m)(m)$1.96M(m)(m)(m)-$3.09M
2017-09-30$25.04M$0.00$965.00K(m)$3.12M$3.23M$18.72M
2017-06-30$157.80K$0.00$493.65K(m)$1.93M$0.00-$1.80M
2017-03-31(m)(m)$953.07K(m)$2.28M$0.00-$1.96M
2016-12-31(m)(m)$773.00K(m)(m)(m)-$1.64M
2016-09-30$321.50K(m)$4.58M(m)(m)$0.00-$6.17M
2016-06-30(m)(m)$2.50M(m)(m)(m)-$3.52M
2016-03-31(m)(m)$2.29M(m)(m)(m)-$5.14M
2015-12-31(m)(m)$1.75M(m)(m)(m)-$3.65M
2015-09-30(m)(m)$1.24M(m)(m)(m)-$692.00K
2015-06-30(m)(m)$1.88M(m)(m)(m)-$2.91M
2015-03-31(m)(m)$1.72M(m)(m)(m)-$3.24M
2014-12-31(m)(m)$2.26M(m)(m)(m)-$2.52M
2014-09-30(m)(m)$4.37M(m)(m)(m)-$5.84M
2014-06-30(m)(m)$2.86M(m)(m)(m)-$4.06M
2014-03-31(m)(m)$2.75M(m)(m)(m)-$3.63M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30(m)(m)(m)(m)(m)$29.00K-$55.99M
2025-06-30(m)$0.00(m)(m)(m)$24.00K-$33.91M
2024-06-30$0.00$263.00K(m)(m)(m)$14.00K-$22.83M
2023-06-30$1.12M$1.26M(m)$5.13M(m)$15.00K-$18.15M
2022-06-30$2.21M$2.29M(m)$14.47M(m)$15.00K-$35.04M
2021-06-30$3.83M$159.00K(m)$12.75M(m)-$188.00K-$47.78M
2020-06-30$4.09M$144.00K(m)(m)(m)-$2.61M-$34.40M
2019-06-30$3.97M-$744.13K(m)(m)$22.86M$184.12K-$13.68M
2018-06-30$9.27M$2.29M$2.73M(m)$18.78M$39.66K-$9.89M
2017-06-30$542.01K$0.00$1.45M(m)$4.22M$0.00-$3.76M
2016-06-30(m)(m)$4.80M(m)(m)(m)-$8.66M
2015-06-30(m)(m)$3.60M(m)(m)(m)-$6.15M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-09-30$0.00(m)(m)(m)(m)$35.00K-$64.54M
2024-09-30$249.00K-$453.00K(m)(m)(m)$0.00$210.00K
2023-09-30$1.35M$1.50M(m)$7.62M(m)$23.00K-$23.38M
2022-09-30$17.16M$2.81M(m)$17.75M(m)$20.00K-$31.85M
2021-09-30$5.18M$1.07M(m)$18.68M(m)-$180.00K-$65.18M
2020-09-30$5.20M$221.00K(m)(m)(m)-$2.61M-$47.86M
2019-09-30$6.17M$3.24M(m)(m)$32.19M$305.76K-$17.69M
2018-09-30$13.34M$5.40M(m)(m)$47.16M$92.08K-$34.49M
2017-09-30$25.58M$0.00$2.41M(m)$7.33M$3.23M$14.96M
2016-09-30$971.99K(m)$9.38M(m)(m)$0.00-$14.83M
2015-09-30(m)(m)$4.84M(m)(m)(m)-$6.84M
2014-09-30(m)(m)$9.98M(m)(m)(m)-$13.53M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-12-31$59.00K(m)(m)(m)(m)$165.00K-$78.26M
2024-12-31$441.00K(m)(m)(m)(m)$114.00K-$35.13M
2023-12-31$1.92M$1.28M(m)$10.30M(m)$14.00K-$31.54M
2022-12-31$18.05M$3.43M(m)$20.71M(m)$28.00K-$41.66M
2021-12-31$5.40M$1.49M(m)(m)(m)-$196.00K-$84.38M
2020-12-31$6.70M$300.00K(m)(m)(m)-$2.79M-$63.50M
2019-12-31$6.75M-$566.52K(m)(m)(m)$280.32K-$16.07M
2018-12-31$7.03M$3.26M$5.79M(m)$57.64M-$49.47K-$40.05M
2017-12-31$27.81M$635.65K$4.37M(m)$13.92M$1.97M$11.87M
2016-12-31$1.15M(m)$10.15M(m)$17.23M$0.00-$16.47M
2015-12-31$0.00(m)$6.59M(m)$11.01M$0.00-$10.49M
2014-12-31(m)(m)$12.24M(m)(m)(m)-$16.06M
2013-12-31(m)(m)$8.91M(m)(m)(m)-$13.05M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Immix Biopharma, Inc. (IMMX)United States$0.837B-18.44
Obsidian Therapeutics, Inc. (OBX)United States$0.829B
ARDELYX, INC. (ARDX)United States$0.857B-22.86
LEXICON PHARMACEUTICALS, INC. (LXRX)United States$0.823B-17.48
GYRE THERAPEUTICS, INC. (GYRE)United States$0.818B-24.71
GERON CORP (GERN)United States$0.803B-12.14
Cryoport, Inc. (CYRX)United States$0.881B-21.29
Theravance Biopharma, Inc. (TBPH)$0.885B16.40
Aclaris Therapeutics, Inc. (ACRS)United States$0.792B-9.78
RIGEL PHARMACEUTICALS INC (RIGL)United States$0.893B2.25